ReviewMaterials today. Bio2026
PMPCylated liposomes in drug delivery and beyond.
Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC) is a zwitterionic polymer that mimics phosphatidylcholine headgroups of cell membrane, exhibiting excellent biocompatibility and antifouling properties. Recently, PMPCylated liposomes, i.e., liposomes functionalized with PMPC chains, have emerged as promising nanocarrier for drug delivery and other biomedical applications. This review summarizes recent progress in the design and application of PMPCylated liposomes, with a focus on their roles in prolonging systemic circulation, enhancing immune evasion, improving boundary lubrication for joint therapy, and overcoming biological barriers such as mucus and BBB. PMPC coatings outperform traditional PEGylation (polyethylene glycol, PEG) by more effectively minimizing protein adsorption, avoiding immune recognition, and enabling repeatable administration without accelerated clearance. Intra-articular PMPCylated liposomes exhibit superlubrication and cartilage adherence, offering both mechanical protection and therapeutic potential in osteoarthritis. In parallel, the hydration layer formed by PMPC facilitates mucus penetration and biofilm disruption, expanding its utility in oral, infectious, and neurological drug delivery. Finally, the clinical translational potential and future design strategies are discussed. Together, these findings highlight PMPCylated liposomes as a versatile and promising platform for drug delivery and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.